The delisting overhang persists despite the equity compliance nod — the bid price extension and the Change-of-Control listing requirement create binary risk. Monitor the next periodic report for equity evidence and the initial listing application timeline. The stock is likely to remain under pressure until both compliance paths are clearly resolved.
Price Chart
Executive Summary
Ensysce Biosciences filed an 8-K disclosing three Nasdaq compliance updates. Nasdaq confirmed the company now complies with the $2.5M stockholders' equity rule (Rule 5550(b)(1)) but warned it must evidence compliance in its next periodic report. The company received a 180-day extension until February 22, 2027, to regain the $1.00 minimum bid price (Rule 5550(a)(2)). Separately, Nasdaq determined the August 5 Cy Biopharma acquisition triggers a Change of Control, requiring the post-transaction company to meet initial listing criteria and complete the initial listing process before shareholder approval of preferred stock conversion — failure risks trading suspension. The company intends to submit an initial listing application. These are procedural updates with no financial figures disclosed, but the delisting risk remains material for a $7M market cap company.
Key Facts
- Nasdaq confirmed compliance with $2.5M stockholders' equity rule (5550(b)(1)) but warned it must be evidenced in the next periodic report.
- Nasdaq granted a 180-day extension until February 22, 2027, to regain the $1.00 minimum bid price compliance (5550(a)(2)).
- Nasdaq determined the August 5 Cy Biopharma acquisition results in a Change of Control under Rule 5110(a), requiring the post-transaction company to satisfy initial listing criteria and complete the initial listing process.
- Failure to meet Nasdaq listing requirements subjects the company to a suspension of trading of its securities.
- The company intends to submit a timely initial listing application for the post-transaction entity.
Financial Impact
No financial figures disclosed; delisting risk for a $7M market cap company with no reported revenue or cash position in this filing.
Risk Factors
- Failure to evidence stockholders' equity compliance in the next periodic report could trigger immediate delisting proceedings.
- The post-Cy Biopharma entity may fail to meet Nasdaq's initial listing criteria, leading to trading suspension.
- The bid price remains below $1.00 with no disclosed plan to regain compliance; the 180-day extension is not a cure.
- Shareholder approval of preferred stock conversion is contingent on initial listing completion, creating a circular dependency.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-040080 |
| Document: 0001493152-26-040080-index.html | 0001493152-26-040080 |
| Document: 0001493152-26-040080.txt | 0001493152-26-040080 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 2d ago | S-3 | $0.4847 | awaiting T+20 | — | $0.4710 (+2.83%) |
Aug 25, 2026 8w ago | 8-K | $0.4120 $0.4001 | ▲ +2.89% | ▲ +3.11% | $0.4710 (−14.32%) |
Jun 29, 2026 17w ago | EFFECT | $0.2967 $0.2614 | ▲ +11.90% | ▲ +11.62% | $0.4710 (−58.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers